News from Abroad: UK Court of Appeal Upholds Invalidity of Enantiomer Patent

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

The "Obvious to Try" Test Is Overused in Assessing Obviousness

The UK Court of Appeal Decision in Novartis AG vs Generics (UK) Ltd (trading as United Kingdom FlagMylan), provides insight into the UK court's approach to judging the validity of patents relating to enantiomers of biologically active compounds.  UK Patent No. 2,203,040 to Novartis AG (and the associated Supplementary Protection Certificate (SPC)) protected rivastigmine, a drug used for the treatment of Alzheimer's disease.  The Court of Appeal held the patent to be invalid on the ground of obviousness and criticised the over-reliance on the "obvious to try" test for assessing obviousness.

The Patent

RivastigmineA chiral compound exists as two or more non-superimposable, mirror-image chemical structures, the alternative structures being known as enantiomers.  Rivastigmine is the (-)enantiomer of the chiral carbamate compound, N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl-carbamate.  UK Patent No. 2,203,040 claims rivastigmine.  The compound is marketed in the UK by Novartis as Exelon®, and is used for the treatment of Alzheimer's disease.

The High Court Decision

The High Court assessed whether it would have been obvious to a skilled person to select RA7, resolve it into its individual enantiomers, and then use the (-) enantiomer as a medicinal product for the treatment of Alzheimer's disease.

A racemic mixture (RA7), a mixture of the (+) and (-) enantiomers of N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl-carbamate, was known at the priority date of the Patent and had been identified as a potential treatment for Alzheimer's disease.

The UK High Court therefore held that it would have been obvious to select the racemic mixture, RA7, to resolve it into its individual enantiomers, and to use the claimed (-) enantiomer for the treatment of Alzheimer's disease.  The Patent and associated SPC were therefore found to be invalid.

The Court of Appeal Decision

NovartisOn appeal, Novartis argued that the High Court erred in its assessment of obviousness.  Novartis argued that that it would not have been "obvious to try" and resolve RA7 into the individual enantiomers, nor would there have been any expectation that the claimed (-) enantiomer would possess improved biological activity compared to the (+) enantiomer.

The Court of Appeal criticised over-reliance on the obvious to try test in assessing inventive step.  The Court of Appeal acknowledged that it might be appropriate when assessing inventive step to ask whether it was obvious to try a particular route with a reasonable expectation of success.  However, the Decision emphasized that such assessment is secondary to the statutory question of whether an invention is obvious:

This is another case in which a patentee defending his patent has attempted to analyse a single multi-faceted question ("was the invention obvious?") by chopping it up into a series of sub-questions, and then treating each of the sub-questions in isolation.  . . .  [T]hat is the wrong approach.

In the present case it was clear that the prior art disclosed a group of compounds, including RA7, that were potentially useful in treating Alzheimer's disease.  Biological data published in the prior art also showed that RA7 was an obvious candidate for further development.  The skilled person was also well aware of the common practice at the priority date to attempt to resolve racemic compounds at an early stage of the drug development process and that there would likely be practical benefits associated with such resolution.

On this evidence the Court of Appeal upheld the judgement of the High Court and the patent was held invalid.

Conclusions

Earlier UK Court of Appeal decisions (Generics (UK) Limited v. Daiichi Pharmaceutical Co Ltd and H Lundbeck A/S v. Generics (UK) Limited) held patents relating to the biologically active enantiomers escitalopram and levofloxacin were non-obvious.  However, evidence in these cases indicated that there were particular problems with resolving the enantiomers at the relevant priority date.  The evidence in the present case indicated that there were no problems encountered in resolving RA7 and that resolution could be achieved using conventional techniques.

The present Decision might suggest that obtaining patent protection for single enantiomers in the UK is likely to prove difficult if the enantiomer was easily resolved from a known racemic mixture.  If data can be produced that demonstrate practical difficulties with isolating an enantiomer from a racemic mixture or an unexpected therapeutic effect associated with the claimed enantiomer then objections of obviousness may be overcome.

This report comes from European Patent Attorneys at WP Thompson & Co., 55 Drury Lane, London UK.  Further details and commentary can be obtained from Gill Smaggasgale, a partner at the firm.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!